- Home
- LIXT vs BLRX Comparison
LIXT vs BLRX Comparison
Compare LIXT & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- BLRX
- Stock Information
- Founded
- LIXT 2005
- BLRX 2003
- Country
- LIXT United States
- BLRX Israel
- Employees
- LIXT N/A
- BLRX N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- LIXT Health Care
- BLRX Health Care
- Exchange
- LIXT Nasdaq
- BLRX Nasdaq
- Market Cap
- LIXT 20.5M
- BLRX 17.1M
- IPO Year
- LIXT N/A
- BLRX 2011
- Fundamental
- Price
- LIXT $4.35
- BLRX $3.50
- Analyst Decision
- LIXT
- BLRX Strong Buy
- Analyst Count
- LIXT 0
- BLRX 2
- Target Price
- LIXT N/A
- BLRX $19.00
- AVG Volume (30 Days)
- LIXT 129.2K
- BLRX 29.2K
- Earning Date
- LIXT 11-07-2025
- BLRX 11-24-2025
- Dividend Yield
- LIXT N/A
- BLRX N/A
- EPS Growth
- LIXT N/A
- BLRX N/A
- EPS
- LIXT N/A
- BLRX N/A
- Revenue
- LIXT N/A
- BLRX $17,251,000.00
- Revenue This Year
- LIXT N/A
- BLRX N/A
- Revenue Next Year
- LIXT N/A
- BLRX N/A
- P/E Ratio
- LIXT N/A
- BLRX N/A
- Revenue Growth
- LIXT N/A
- BLRX 1.19
- 52 Week Low
- LIXT $0.64
- BLRX $2.30
- 52 Week High
- LIXT $6.26
- BLRX $22.60
- Technical
- Relative Strength Index (RSI)
- LIXT 45.71
- BLRX 37.77
- Support Level
- LIXT $4.05
- BLRX $3.51
- Resistance Level
- LIXT $4.42
- BLRX $3.89
- Average True Range (ATR)
- LIXT 0.40
- BLRX 0.24
- MACD
- LIXT -0.04
- BLRX -0.04
- Stochastic Oscillator
- LIXT 41.51
- BLRX 0.00
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.